TEST:

Galen™ Breast HER2

"Ibex Medical Analytics (Ibex)...announced the publication of a clinical study evaluating Ibex's Galen platform, published in the peer-reviewed journal Pathology, which demonstrated excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies.... During the study, Galen Prostate demonstrated high accuracy in detecting prostate adenocarcinoma with an Area Under the Curve (AUC) of 0.988. The AI algorithm was also highly accurate in cancer grading, specifically differentiating between low and medium/high-grade Gleason scores with an AUC of 0.994, as well as in identifying perineural invasion. In several cases, Galen Prostate's AI algorithm accurately identified higher Gleason scores than previously evaluated by a pathologist and unveiled previously undetected cancer, showcasing its potential to enhance diagnostic accuracy and reduce inter-observer variability."

"These studies, highlighting the value of Ibex's AI-powered cancer diagnostics...A study conducted at Brigham and Women's Hospital and Champalimaud Foundation evaluated Galen Breast's performance in identifying microinvasive carcinoma of the breast in a challenging patient cohort. Microinvasive carcinoma is defined as the focus of invasive breast cancer no larger than 1mm, in which accurate detection has important implications for patient management. The results indicate that Galen Breast's AI algorithm is highly accurate in detecting microinvasive lesions and has the potential to improve consistency in diagnosis and support more efficient workflows in pathology laboratories...The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting, with NPV and PPV of 0.99....Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755."

Pathologists supported by AI showed improvements in HER2 scoring consistency, and a trend for better accuracy overall and for the analyzed clinical cut-offs. These results suggest AI may improve reproducibility and standardization of HER2 scoring and will be validated in additional ongoing studies.

"Ibex Medical Analytics (Ibex)...and CorePlus Servicios Clínicos y Patológicos...announced CorePlus has diagnosed over 10,000 cases using Galen™, Ibex’s AI-powered cancer diagnostics platform. In a significant boost to patient outcomes, pathologists used AI-driven insights from Galen to correct the diagnosis of over 150 patients."

"Ibex Medical Analytics (Ibex)...announced the launch of Galen™ Breast HER2, an AI-powered solution that aids pathologists in setting a higher standard for accurate and reproducible HER2 (human epidermal growth factor receptor 2) scoring in breast cancer patients."